This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AbbVie moves to dismiss US antitrust case over Humira

( April 14, 2025, 22:31 GMT | Official Statement) -- MLex Summary: AbbVie told a US federal court that responding to biosimilar competition to its branded drug Humira by launching innovative new drugs, reducing prices for health plans, and increasing choices for doctors that are cost-neutral to patients are all things antitrust law encourages. AbbVie moved to dismiss claims that it entered into illegal agreements with pharmacy benefit managers to ensure that Humira would be positioned favorably on formularies. “Plaintiff’s theory is that, if patients had to pay more for Humira, at least some doctors would not view it as a viable option and would not prescribe it. At bottom, plaintiff is upset because Humira does not cost patients more and because, as a result, doctors continue to prescribe it instead of biosimilars. That is not a harm antitrust law was designed to remedy,” AbbVie argued.See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections